Home > Press Releases > Antibody-Drug Conjugates (ADCS) Market

Antibody-Drug Conjugates (ADCS) Market Likely to Surpass USD 51.6 Billion by 2035

Report Code: HC-52647  |  Published in: Oct 2025, By MarketGenics  |  Number of pages: 311
Get PDF
Buy

Exploring novel growth opportunities on, “Antibody-Drug Conjugates (ADCS) Market Size, Share & Trends Analysis Report by Molecule (Monoclonal IgG1-based ADCs, Monoclonal IgG2-based ADCs, Monoclonal IgG4-based ADCs, Bispecific antibody-based ADCs, Fragment antigen-binding (Fab/F(ab’)2) ADCs, Single-domain (nanobody) ADCs, Site-specific conjugated ADC, Others), Payload / Cytotoxic Warhead Class, Linker Chemistry, Developmental Stage, Therapeutic Indication, End-users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A comprehensive exploration of emerging market pathways in the antibody-drug conjugates market uncovers key growth drivers including niche market leadership, technology-enabled distribution, and evolving consumer needs underscoring market’s potential to scale globally.

Global Antibody-Drug Conjugates (ADCS) Market Forecast 2035:

The global antibody-drug conjugates (ADCs) market is projected to expand from USD 14.3 billion in 2025 to USD 51.6 billion by 2035, registering a robust CAGR of 13.7% over the forecast period.  The global antibody-drug conjugates (ADCs) market is expected to grow significantly as the increasing demand of the targeted cancer-targeted therapies increases the effects on improving treatment efficacy with minimum systemic toxicity. ADCs which is a form of drug that entails the use of monoclonal antibodies and extremely strong cytotoxic molecules are gaining popularity based on their ability to take drugs that eliminate tumor cells to the cancer victim in comparison to the traditional treatments.

A continuous advancement in the field of linker technologies, the emergence of next-generation payloads that are more potent and more selective, and the introduction of bispecific and multi-target ADCs are contributing to the sustained growth of the market. Pharmaceutical and biotechnology companies are fiercely working on the creation of drugs and forming alliances to strengthen the ADC pipeline, accelerate clinical trials, and get regulatory approval.

The market is also experiencing more ADCs in late-stage clinical development, migration into new areas of treatment of cancer indications that are difficult to treat, and increased use by health professionals demanding more specific and personalized forms of treatment. The increased awareness of targeted therapies and favorable reimbursement policies is also increasing market penetration.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Antibody-Drug Conjugates (ADCS) Market

Pharmaceutical and biotechnology firms are hugely expanding their research and development in order to develop next-generation ADCs that are more effective, selective, and with lower systemic toxicity. R&D activities not only hasten clinical progression, but also raise the chances of regulatory acceptance and market acceptance, and enhance the commercial potential of ADC therapies. As an instance, Seagen Inc. made a statement about its long-term investment into the implementation of the ADC pipeline that would include the creation of next-generation payloads and bispecific ADCs which would address multiple cancer antigens.

The major drawback is the innovation of ADCs, associated with complex scientific and technical issues, especially concerning the development of linkers that are stable in the circulation and release the cytotoxic payload successfully at the tumor location. These obstacles lead to the prolonged development schedule, higher R and D expenses, and risky chances of trial failure. The fact that ADC design is a complex technique and conjugation chemistry requires accurate results makes the development process resource-intensive, which reduces the rapid entries of new therapies into the market.

The combination of immunotherapies and ADCs, including checkpoint inhibitors, forms an important growth opportunity in the oncology market. ADC combination strategies offer pharmaceutical firms with a channel through which they can differentiate their products and gain a larger market share in the oncology therapeutic market. As an instance, in 2025, Gilead Sciences launched a Phase 3 clinical trial to combine its ADC Trodelvy (sacituzumab govitecan) with an anti-PD-1 drug by Merck known as Keytruda (pembrolizumab) to first-line treat PD-L1-expressing advanced triple-negative breast cancer (TNBC). This combination showed that the risk of cancer progression is reduced by 35%.

Expansion of Global Antibody-Drug Conjugates (ADCS) Market

“Innovation, pharma demand propels the global Antibody-Drug Conjugates (ADCS) market expansion”

  • The global antibody-drug conjugates (ADCS) market continues to expand due to the innovations that have taken place including next-generation linker technologies, high-potency and selective payloads, bispecific and multi-target ADCs, and combination therapies with immunotherapies or checkpoint inhibitors, that are growing the therapeutic use of ADCs and improving patient outcomes. Clarity Pharmaceuticals is the first to develop theranostic ADCs with copper-based radionuclides rather than iodine-based radionuclides in imaging and therapy. Cu-64/67-SAR-Trastuzumab, an anti-HER2 targeted therapy and imaging agent, has allowed the company to demonstrate good preclinical results.
  • The encouragement of the government and the connections between the academic sphere and the industrial world are accelerating ADCs market, particularly in North America and Asia-Pacific. As an instance, the U.S. National Cancer Institute (NCI) created the SBIR funding opportunity, Antibody-Drug Conjugates as Radiopharmaceutical Theranostics in Cancer, in 2025 to support ADCs that combine diagnostic and therapeutic radionuclides and provides up to Phase I funding of up to $400,000 and Phase II funding to up to $2.25 million.

Regional Analysis of Global Antibody-Drug Conjugates (ADCS) Market

  • North America leads the ADC market, supported by a robust network of biotech clusters, pharmaceutical companies, and advanced research centers driving innovation in targeted oncology therapies. Having extensive clinical trial facilities and state-of-the-art manufacturing facilities allows developing, testing and commercializing ADC candidates in a relatively short time. In 2025, Seagen and Genentech collaborated to develop the next generation ADCs based on AI-driven platforms to optimize linker and payload design and increase the pipeline development. The investments and adoption are further accelerated by government sponsorship and industry-academic partnerships that facilitate development of precision therapies. All these ensure the role of the region as a center of ADC innovation and increase the prospects of treating cancer at a higher level.
  • Asia-Pacific ADC market is the fastest developing market due to the growing cancer prevalence, growing healthcare investments, and biopharmaceutical infrastructure. The increased funding of the government, change of regulations, and the formation of successful partnerships between local and international pharmaceutical firms are fueling the evolution and implementation of targeted therapies. The Asia-Pacific ADC market is being propelled by China, Japan, and South Korea with the development of the biotech industry in China, sophisticated pharma in Japan, and the presence of increasing R&D and partnership in South Korea.

Prominent players operating in the global antibody-drug conjugates (ADCS) market are AbbVie Inc., ADC Therapeutics, Ambrx Biopharma, Amgen Inc., Astellas Pharma Inc., AstraZeneca, Byondis, Catalent plc, Daiichi Sankyo Company, Limited, Genentech, Genmab A/S, ImmunoGen, Inc., Johnson & Johnson, Merck & Co., Inc., NBE-Therapeutics AG, Pfizer Inc., RemeGen, Roche Holding AG, Synaffix B.V., and Other Key Players.

The global Antibody-Drug Conjugates (ADCS) market has been segmented as follows:

Global Antibody-Drug Conjugates (ADCS) Market Analysis, By Molecule

  • Monoclonal IgG1-based ADCs
  • Monoclonal IgG2-based ADCs
  • Monoclonal IgG4-based ADCs
  • Bispecific antibody-based ADCs
  • Fragment antigen-binding (Fab/F(ab’)2) ADCs
  • Single-domain (nanobody) ADCs
  • Site-specific conjugated ADC
  • Others

Global Antibody-Drug Conjugates (ADCS) Market Analysis, By Payload / Cytotoxic Warhead Class

  • Microtubule inhibitors
  • Topoisomerase I inhibitors
  • DNA-alkylating agents
  • DNA cross-linkers
  • Proteasome inhibitors as payloads
  • Immune-stimulatory payloads
  • Radiolabeled payloads
  • Others

Global Antibody-Drug Conjugates (ADCS) Market Analysis, By Linker Chemistry

  • Cleavable peptide linkers
  • Acid-labile cleavable linkers
  • Disulfide/reducible cleavable linkers
  • Non-cleavable thioether linkers
  • SMCC / maleimide chemistries
  • Others

Global Antibody-Drug Conjugates (ADCS) Market Analysis, By Developmental Stage

  • Preclinical discovery and validation ADCs
  • IND-enabling / Translational ADC programs
  • Phase I clinical ADCs
  • Phase II clinical ADCs
  • Phase III clinical ADCs
  • Commercially approved ADCs

Global Antibody-Drug Conjugates (ADCS) Market Analysis, By Therapeutic Indication

  • Oncology
    • Solid tumours
    • Hematologic malignancies
    • Rare and niche tumour indications
    • Immuno-oncology combination ADCs
  • Non-oncology targeted therapies
  • Others

Global Antibody-Drug Conjugates (ADCS) Market Analysis, by End Users

  • Oncology Specialty Hospitals
  • Community Oncology Clinics
  • Pharmaceutical & Biotech Innovators
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Diagnostic & Pathology Laboratories
  • Hospital Pharmacies and Compounding Facilities
  • Contract Research Organizations (CROs)
  • Academic Research Institutes
  • Health Technology Assessment (HTA) Bodies
  • Others

Global Antibody-Drug Conjugates (ADCS) Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America
 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Antibody-Drug Conjugates (ADCS) Market Outlook
      • 2.1.1. Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Growing demand for RNA-based therapeutics in oncology and rare diseases
        • 4.1.1.2. Growing clinical pipeline, regulatory approvals and industry R&D/collaborations
        • 4.1.1.3. Advances in ADC technology (better antibodies, linkers and payloads)
      • 4.1.2. Restraints
        • 4.1.2.1. High development and complex, costly manufacturing requirements for ADCs
        • 4.1.2.2. Safety/toxicity concerns and occasional late-stage clinical failures/regulatory setbacks
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Antibody-Drug Conjugates (ADCS) Market Demand
      • 4.7.1. Historical Market Size - in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size - in Value (US$ Bn), 2025–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Antibody-Drug Conjugates (ADCS) Market Analysis, By Molecule
    • 6.1. Key Segment Analysis
    • 6.2. Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), Analysis, and Forecasts, By Molecule, 2021-2035
      • 6.2.1. Monoclonal IgG1-based ADCs
      • 6.2.2. Monoclonal IgG2-based ADCs
      • 6.2.3. Monoclonal IgG4-based ADCs
      • 6.2.4. Bispecific antibody-based ADCs
      • 6.2.5. Fragment antigen-binding (Fab/F(ab’)2) ADCs
      • 6.2.6. Single-domain (nanobody) ADCs
      • 6.2.7. Site-specific conjugated ADC
      • 6.2.8. Others
  • 7. Global Antibody-Drug Conjugates (ADCS) Market Analysis, By Payload / Cytotoxic Warhead Class
    • 7.1. Key Segment Analysis
    • 7.2. Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), Analysis, and Forecasts, By Payload / Cytotoxic Warhead Class, 2021-2035
      • 7.2.1. Microtubule inhibitors
      • 7.2.2. Topoisomerase I inhibitors
      • 7.2.3. DNA-alkylating agents
      • 7.2.4. DNA cross-linkers
      • 7.2.5. Proteasome inhibitors as payloads
      • 7.2.6. Immune-stimulatory payloads
      • 7.2.7. Radiolabeled payloads
      • 7.2.8. Others
  • 8. Global Antibody-Drug Conjugates (ADCS) Market Analysis and Forecasts, By Linker Chemistry
    • 8.1. Key Findings
    • 8.2. Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Mn), Analysis, and Forecasts, By Linker Chemistry, 2021-2035
      • 8.2.1. Cleavable peptide linkers
      • 8.2.2. Acid-labile cleavable linkers
      • 8.2.3. Disulfide/reducible cleavable linkers
      • 8.2.4. Non-cleavable thioether linkers
      • 8.2.5. SMCC / maleimide chemistries
      • 8.2.6. Others
  • 9. Global Antibody-Drug Conjugates (ADCS) Market Analysis and Forecasts, By Developmental Stage
    • 9.1. Key Findings
    • 9.2. Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Mn), Analysis, and Forecasts, By Developmental Stage, 2021-2035
      • 9.2.1. Preclinical discovery and validation ADCs
      • 9.2.2. IND-enabling / Translational ADC programs
      • 9.2.3. Phase I clinical ADCs
      • 9.2.4. Phase II clinical ADCs
      • 9.2.5. Phase III clinical ADCs
      • 9.2.6. Commercially approved ADCs
  • 10. Global Antibody-Drug Conjugates (ADCS) Market Analysis and Forecasts, By Therapeutic Indication
    • 10.1. Key Findings
    • 10.2. Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Mn), Analysis, and Forecasts, By Therapeutic Indication, 2021-2035
      • 10.2.1. Oncology
        • 10.2.1.1. Solid tumours
        • 10.2.1.2. Hematologic malignancies
        • 10.2.1.3. Rare and niche tumour indications
        • 10.2.1.4. Immuno-oncology combination ADCs
      • 10.2.2. Non-oncology targeted therapies
      • 10.2.3. Others
  • 11. Global Antibody-Drug Conjugates (ADCS) Market Analysis and Forecasts, By End-users
    • 11.1. Key Findings
    • 11.2. Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Mn), Analysis, and Forecasts, By End-users, 2021-2035
      • 11.2.1. Oncology Specialty Hospitals
      • 11.2.2. Community Oncology Clinics
      • 11.2.3. Pharmaceutical & Biotech Innovators
      • 11.2.4. Contract Development & Manufacturing Organizations (CDMOs)
      • 11.2.5. Diagnostic & Pathology Laboratories
      • 11.2.6. Hospital Pharmacies and Compounding Facilities
      • 11.2.7. Contract Research Organizations (CROs)
      • 11.2.8. Academic Research Institutes
      • 11.2.9. Health Technology Assessment (HTA) Bodies
      • 11.2.10. Others
  • 12. Global Antibody-Drug Conjugates (ADCS) Market Analysis and Forecasts, by Region
    • 12.1. Key Findings
    • 12.2. Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
      • 12.2.1. North America
      • 12.2.2. Europe
      • 12.2.3. Asia Pacific
      • 12.2.4. Middle East
      • 12.2.5. Africa
      • 12.2.6. South America
  • 13. North America Antibody-Drug Conjugates (ADCS) Market Analysis
    • 13.1. Key Segment Analysis
    • 13.2. Regional Snapshot
    • 13.3. North America Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 13.3.1. Molecule
      • 13.3.2. Payload / Cytotoxic Warhead Class
      • 13.3.3. Linker Chemistry
      • 13.3.4. Developmental Stage
      • 13.3.5. Therapeutic Indication
      • 13.3.6. End-users
      • 13.3.7. Country
        • 13.3.7.1. USA
        • 13.3.7.2. Canada
        • 13.3.7.3. Mexico
    • 13.4. USA Antibody-Drug Conjugates (ADCS) Market
      • 13.4.1. Country Segmental Analysis
      • 13.4.2. Molecule
      • 13.4.3. Payload / Cytotoxic Warhead Class
      • 13.4.4. Linker Chemistry
      • 13.4.5. Developmental Stage
      • 13.4.6. Therapeutic Indication
      • 13.4.7. End-users
    • 13.5. Canada Antibody-Drug Conjugates (ADCS) Market
      • 13.5.1. Country Segmental Analysis
      • 13.5.2. Molecule
      • 13.5.3. Payload / Cytotoxic Warhead Class
      • 13.5.4. Linker Chemistry
      • 13.5.5. Developmental Stage
      • 13.5.6. Therapeutic Indication
      • 13.5.7. End-users
    • 13.6. Mexico Antibody-Drug Conjugates (ADCS) Market
      • 13.6.1. Country Segmental Analysis
      • 13.6.2. Molecule
      • 13.6.3. Payload / Cytotoxic Warhead Class
      • 13.6.4. Linker Chemistry
      • 13.6.5. Developmental Stage
      • 13.6.6. Therapeutic Indication
      • 13.6.7. End-users
  • 14. Europe Antibody-Drug Conjugates (ADCS) Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. Europe Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Molecule
      • 14.3.2. Payload / Cytotoxic Warhead Class
      • 14.3.3. Linker Chemistry
      • 14.3.4. Developmental Stage
      • 14.3.5. Therapeutic Indication
      • 14.3.6. End-users
      • 14.3.7. Country
        • 14.3.7.1. Germany
        • 14.3.7.2. United Kingdom
        • 14.3.7.3. France
        • 14.3.7.4. Italy
        • 14.3.7.5. Spain
        • 14.3.7.6. Netherlands
        • 14.3.7.7. Nordic Countries
        • 14.3.7.8. Poland
        • 14.3.7.9. Russia & CIS
        • 14.3.7.10. Rest of Europe
    • 14.4. Germany Antibody-Drug Conjugates (ADCS) Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Molecule
      • 14.4.3. Payload / Cytotoxic Warhead Class
      • 14.4.4. Linker Chemistry
      • 14.4.5. Developmental Stage
      • 14.4.6. Therapeutic Indication
      • 14.4.7. End-users
    • 14.5. United Kingdom Antibody-Drug Conjugates (ADCS) Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Molecule
      • 14.5.3. Payload / Cytotoxic Warhead Class
      • 14.5.4. Linker Chemistry
      • 14.5.5. Developmental Stage
      • 14.5.6. Therapeutic Indication
      • 14.5.7. End-users
    • 14.6. France Antibody-Drug Conjugates (ADCS) Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Molecule
      • 14.6.3. Payload / Cytotoxic Warhead Class
      • 14.6.4. Linker Chemistry
      • 14.6.5. Developmental Stage
      • 14.6.6. Therapeutic Indication
      • 14.6.7. End-users
    • 14.7. Italy Antibody-Drug Conjugates (ADCS) Market
      • 14.7.1. Country Segmental Analysis
      • 14.7.2. Molecule
      • 14.7.3. Payload / Cytotoxic Warhead Class
      • 14.7.4. Linker Chemistry
      • 14.7.5. Developmental Stage
      • 14.7.6. Therapeutic Indication
      • 14.7.7. End-users
    • 14.8. Spain Antibody-Drug Conjugates (ADCS) Market
      • 14.8.1. Country Segmental Analysis
      • 14.8.2. Molecule
      • 14.8.3. Payload / Cytotoxic Warhead Class
      • 14.8.4. Linker Chemistry
      • 14.8.5. Developmental Stage
      • 14.8.6. Therapeutic Indication
      • 14.8.7. End-users
    • 14.9. Netherlands Antibody-Drug Conjugates (ADCS) Market
      • 14.9.1. Country Segmental Analysis
      • 14.9.2. Molecule
      • 14.9.3. Payload / Cytotoxic Warhead Class
      • 14.9.4. Linker Chemistry
      • 14.9.5. Developmental Stage
      • 14.9.6. Therapeutic Indication
      • 14.9.7. End-users
    • 14.10. Nordic Countries Antibody-Drug Conjugates (ADCS) Market
      • 14.10.1. Country Segmental Analysis
      • 14.10.2. Molecule
      • 14.10.3. Payload / Cytotoxic Warhead Class
      • 14.10.4. Linker Chemistry
      • 14.10.5. Developmental Stage
      • 14.10.6. Therapeutic Indication
      • 14.10.7. End-users
    • 14.11. Poland Antibody-Drug Conjugates (ADCS) Market
      • 14.11.1. Country Segmental Analysis
      • 14.11.2. Molecule
      • 14.11.3. Payload / Cytotoxic Warhead Class
      • 14.11.4. Linker Chemistry
      • 14.11.5. Developmental Stage
      • 14.11.6. Therapeutic Indication
      • 14.11.7. End-users
    • 14.12. Russia & CIS Antibody-Drug Conjugates (ADCS) Market
      • 14.12.1. Country Segmental Analysis
      • 14.12.2. Molecule
      • 14.12.3. Payload / Cytotoxic Warhead Class
      • 14.12.4. Linker Chemistry
      • 14.12.5. Developmental Stage
      • 14.12.6. Therapeutic Indication
      • 14.12.7. End-users
    • 14.13. Rest of Europe Antibody-Drug Conjugates (ADCS) Market
      • 14.13.1. Country Segmental Analysis
      • 14.13.2. Molecule
      • 14.13.3. Payload / Cytotoxic Warhead Class
      • 14.13.4. Linker Chemistry
      • 14.13.5. Developmental Stage
      • 14.13.6. Therapeutic Indication
      • 14.13.7. End-users
  • 15. Asia Pacific Antibody-Drug Conjugates (ADCS) Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. East Asia Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Molecule
      • 15.3.2. Payload / Cytotoxic Warhead Class
      • 15.3.3. Linker Chemistry
      • 15.3.4. Developmental Stage
      • 15.3.5. Therapeutic Indication
      • 15.3.6. End-users
      • 15.3.7. Country
        • 15.3.7.1. China
        • 15.3.7.2. India
        • 15.3.7.3. Japan
        • 15.3.7.4. South Korea
        • 15.3.7.5. Australia and New Zealand
        • 15.3.7.6. Indonesia
        • 15.3.7.7. Malaysia
        • 15.3.7.8. Thailand
        • 15.3.7.9. Vietnam
        • 15.3.7.10. Rest of Asia Pacific
    • 15.4. China Antibody-Drug Conjugates (ADCS) Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Molecule
      • 15.4.3. Payload / Cytotoxic Warhead Class
      • 15.4.4. Linker Chemistry
      • 15.4.5. Developmental Stage
      • 15.4.6. Therapeutic Indication
      • 15.4.7. End-users
    • 15.5. India Antibody-Drug Conjugates (ADCS) Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Molecule
      • 15.5.3. Payload / Cytotoxic Warhead Class
      • 15.5.4. Linker Chemistry
      • 15.5.5. Developmental Stage
      • 15.5.6. Therapeutic Indication
      • 15.5.7. End-users
    • 15.6. Japan Antibody-Drug Conjugates (ADCS) Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Molecule
      • 15.6.3. Payload / Cytotoxic Warhead Class
      • 15.6.4. Linker Chemistry
      • 15.6.5. Developmental Stage
      • 15.6.6. Therapeutic Indication
      • 15.6.7. End-users
    • 15.7. South Korea Antibody-Drug Conjugates (ADCS) Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Molecule
      • 15.7.3. Payload / Cytotoxic Warhead Class
      • 15.7.4. Linker Chemistry
      • 15.7.5. Developmental Stage
      • 15.7.6. Therapeutic Indication
      • 15.7.7. End-users
    • 15.8. Australia and New Zealand Antibody-Drug Conjugates (ADCS) Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Molecule
      • 15.8.3. Payload / Cytotoxic Warhead Class
      • 15.8.4. Linker Chemistry
      • 15.8.5. Developmental Stage
      • 15.8.6. Therapeutic Indication
      • 15.8.7. End-users
    • 15.9. Indonesia Antibody-Drug Conjugates (ADCS) Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Molecule
      • 15.9.3. Payload / Cytotoxic Warhead Class
      • 15.9.4. Linker Chemistry
      • 15.9.5. Developmental Stage
      • 15.9.6. Therapeutic Indication
      • 15.9.7. End-users
    • 15.10. Malaysia Antibody-Drug Conjugates (ADCS) Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Molecule
      • 15.10.3. Payload / Cytotoxic Warhead Class
      • 15.10.4. Linker Chemistry
      • 15.10.5. Developmental Stage
      • 15.10.6. Therapeutic Indication
      • 15.10.7. End-users
    • 15.11. Thailand Antibody-Drug Conjugates (ADCS) Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Molecule
      • 15.11.3. Payload / Cytotoxic Warhead Class
      • 15.11.4. Linker Chemistry
      • 15.11.5. Developmental Stage
      • 15.11.6. Therapeutic Indication
      • 15.11.7. End-users
    • 15.12. Vietnam Antibody-Drug Conjugates (ADCS) Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Molecule
      • 15.12.3. Payload / Cytotoxic Warhead Class
      • 15.12.4. Linker Chemistry
      • 15.12.5. Developmental Stage
      • 15.12.6. Therapeutic Indication
      • 15.12.7. End-users
    • 15.13. Rest of Asia Pacific Antibody-Drug Conjugates (ADCS) Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Molecule
      • 15.13.3. Payload / Cytotoxic Warhead Class
      • 15.13.4. Linker Chemistry
      • 15.13.5. Developmental Stage
      • 15.13.6. Therapeutic Indication
      • 15.13.7. End-users
  • 16. Middle East Antibody-Drug Conjugates (ADCS) Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Middle East Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Molecule
      • 16.3.2. Payload / Cytotoxic Warhead Class
      • 16.3.3. Linker Chemistry
      • 16.3.4. Developmental Stage
      • 16.3.5. Therapeutic Indication
      • 16.3.6. End-users
      • 16.3.7. Country
        • 16.3.7.1. Turkey
        • 16.3.7.2. UAE
        • 16.3.7.3. Saudi Arabia
        • 16.3.7.4. Israel
        • 16.3.7.5. Rest of Middle East
    • 16.4. Turkey Antibody-Drug Conjugates (ADCS) Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Molecule
      • 16.4.3. Payload / Cytotoxic Warhead Class
      • 16.4.4. Linker Chemistry
      • 16.4.5. Developmental Stage
      • 16.4.6. Therapeutic Indication
      • 16.4.7. End-users
    • 16.5. UAE Antibody-Drug Conjugates (ADCS) Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Molecule
      • 16.5.3. Payload / Cytotoxic Warhead Class
      • 16.5.4. Linker Chemistry
      • 16.5.5. Developmental Stage
      • 16.5.6. Therapeutic Indication
      • 16.5.7. End-users
    • 16.6. Saudi Arabia Antibody-Drug Conjugates (ADCS) Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Molecule
      • 16.6.3. Payload / Cytotoxic Warhead Class
      • 16.6.4. Linker Chemistry
      • 16.6.5. Developmental Stage
      • 16.6.6. Therapeutic Indication
      • 16.6.7. End-users
    • 16.7. Israel Antibody-Drug Conjugates (ADCS) Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Molecule
      • 16.7.3. Payload / Cytotoxic Warhead Class
      • 16.7.4. Linker Chemistry
      • 16.7.5. Developmental Stage
      • 16.7.6. Therapeutic Indication
      • 16.7.7. End-users
    • 16.8. Rest of Middle East Antibody-Drug Conjugates (ADCS) Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Molecule
      • 16.8.3. Payload / Cytotoxic Warhead Class
      • 16.8.4. Linker Chemistry
      • 16.8.5. Developmental Stage
      • 16.8.6. Therapeutic Indication
      • 16.8.7. End-users
  • 17. Africa Antibody-Drug Conjugates (ADCS) Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Africa Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Molecule
      • 17.3.2. Payload / Cytotoxic Warhead Class
      • 17.3.3. Linker Chemistry
      • 17.3.4. Developmental Stage
      • 17.3.5. Therapeutic Indication
      • 17.3.6. End-users
      • 17.3.7. Country
        • 17.3.7.1. South Africa
        • 17.3.7.2. Egypt
        • 17.3.7.3. Nigeria
        • 17.3.7.4. Algeria
        • 17.3.7.5. Rest of Africa
    • 17.4. South Africa Antibody-Drug Conjugates (ADCS) Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Molecule
      • 17.4.3. Payload / Cytotoxic Warhead Class
      • 17.4.4. Linker Chemistry
      • 17.4.5. Developmental Stage
      • 17.4.6. Therapeutic Indication
      • 17.4.7. End-users
    • 17.5. Egypt Antibody-Drug Conjugates (ADCS) Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Molecule
      • 17.5.3. Payload / Cytotoxic Warhead Class
      • 17.5.4. Linker Chemistry
      • 17.5.5. Developmental Stage
      • 17.5.6. Therapeutic Indication
      • 17.5.7. End-users
    • 17.6. Nigeria Antibody-Drug Conjugates (ADCS) Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Molecule
      • 17.6.3. Payload / Cytotoxic Warhead Class
      • 17.6.4. Linker Chemistry
      • 17.6.5. Developmental Stage
      • 17.6.6. Therapeutic Indication
      • 17.6.7. End-users
    • 17.7. Algeria Antibody-Drug Conjugates (ADCS) Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Molecule
      • 17.7.3. Payload / Cytotoxic Warhead Class
      • 17.7.4. Linker Chemistry
      • 17.7.5. Developmental Stage
      • 17.7.6. Therapeutic Indication
      • 17.7.7. End-users
    • 17.8. Rest of Africa Antibody-Drug Conjugates (ADCS) Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Molecule
      • 17.8.3. Payload / Cytotoxic Warhead Class
      • 17.8.4. Linker Chemistry
      • 17.8.5. Developmental Stage
      • 17.8.6. Therapeutic Indication
      • 17.8.7. End-users
  • 18. South America Antibody-Drug Conjugates (ADCS) Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Central and South Africa Antibody-Drug Conjugates (ADCS) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Molecule
      • 18.3.2. Payload / Cytotoxic Warhead Class
      • 18.3.3. Linker Chemistry
      • 18.3.4. Developmental Stage
      • 18.3.5. Therapeutic Indication
      • 18.3.6. End-users
      • 18.3.7. Country
        • 18.3.7.1. Brazil
        • 18.3.7.2. Argentina
        • 18.3.7.3. Rest of South America
    • 18.4. Brazil Antibody-Drug Conjugates (ADCS) Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Molecule
      • 18.4.3. Payload / Cytotoxic Warhead Class
      • 18.4.4. Linker Chemistry
      • 18.4.5. Developmental Stage
      • 18.4.6. Therapeutic Indication
      • 18.4.7. End-users
    • 18.5. Argentina Antibody-Drug Conjugates (ADCS) Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Molecule
      • 18.5.3. Payload / Cytotoxic Warhead Class
      • 18.5.4. Linker Chemistry
      • 18.5.5. Developmental Stage
      • 18.5.6. Therapeutic Indication
      • 18.5.7. End-users
    • 18.6. Rest of South America Antibody-Drug Conjugates (ADCS) Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Molecule
      • 18.6.3. Payload / Cytotoxic Warhead Class
      • 18.6.4. Linker Chemistry
      • 18.6.5. Developmental Stage
      • 18.6.6. Therapeutic Indication
      • 18.6.7. End-users
  • 19. Key Players/ Company Profile
    • 19.1. AbbVie Inc.
      • 19.1.1. Company Details/ Overview
      • 19.1.2. Company Financials
      • 19.1.3. Key Customers and Competitors
      • 19.1.4. Business/ Industry Portfolio
      • 19.1.5. Product Portfolio/ Specification Details
      • 19.1.6. Pricing Data
      • 19.1.7. Strategic Overview
      • 19.1.8. Recent Developments
    • 19.2. ADC Therapeutics
    • 19.3. Ambrx Biopharma
    • 19.4. Amgen Inc.
    • 19.5. Astellas Pharma Inc.
    • 19.6. AstraZeneca
    • 19.7. Byondis
    • 19.8. Catalent plc
    • 19.9. Daiichi Sankyo Company, Limited
    • 19.10. Genentech
    • 19.11. Genmab A/S
    • 19.12. ImmunoGen, Inc.
    • 19.13. Johnson & Johnson
    • 19.14. Merck & Co., Inc.
    • 19.15. NBE-Therapeutics AG
    • 19.16. Pfizer Inc.
    • 19.17. RemeGen
    • 19.18. Roche Holding AG
    • 19.19. Synaffix B.V.
    • 19.20. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation